These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 32579503)
1. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment. Singh A; Shafi S; Upadhyay T; Najmi AK; Kohli K; Pottoo FH Curr Top Med Chem; 2020; 20(20):1839-1854. PubMed ID: 32579503 [TBL] [Abstract][Full Text] [Related]
2. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758 [TBL] [Abstract][Full Text] [Related]
3. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Kumar V; Rahman M; Gahtori P; Al-Abbasi F; Anwar F; Kim HS Expert Opin Drug Deliv; 2021 Jun; 18(6):673-694. PubMed ID: 33295218 [TBL] [Abstract][Full Text] [Related]
4. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062 [TBL] [Abstract][Full Text] [Related]
5. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence. Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690 [TBL] [Abstract][Full Text] [Related]
6. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. Elnaggar MH; Abushouk AI; Hassan AHE; Lamloum HM; Benmelouka A; Moatamed SA; Abd-Elmegeed H; Attia S; Samir A; Amr N; Johar D; Zaky S Semin Cancer Biol; 2021 Feb; 69():91-99. PubMed ID: 31421265 [TBL] [Abstract][Full Text] [Related]
7. The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma. Zhang Z; Song L; Guo J Pharm Nanotechnol; 2018; 6(4):221-231. PubMed ID: 30277174 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in hepatocellular carcinoma-targeted nanoparticles. Liu X; Bai Y; Zhou B; Yao W; Song S; Liu J; Zheng C Biomed Mater; 2024 May; 19(4):. PubMed ID: 38697209 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. Varshosaz J; Farzan M World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089 [TBL] [Abstract][Full Text] [Related]
10. Advanced therapeutics avenues in hepatocellular carcinoma: a novel paradigm. Javed ; Yadav S Med Oncol; 2023 Jul; 40(8):239. PubMed ID: 37442842 [TBL] [Abstract][Full Text] [Related]
11. Nanomedicines: a theranostic approach for hepatocellular carcinoma. Usmani A; Mishra A; Ahmad M Artif Cells Nanomed Biotechnol; 2018 Jun; 46(4):680-690. PubMed ID: 28884605 [TBL] [Abstract][Full Text] [Related]
12. Magnetic Nanoparticles for Hepatocellular Carcinoma Diagnosis and Therapy. Ungureanu BS; Teodorescu CM; Săftoiu A J Gastrointestin Liver Dis; 2016 Sep; 25(3):375-83. PubMed ID: 27689203 [TBL] [Abstract][Full Text] [Related]
13. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Zhang X; Ng HLH; Lu A; Lin C; Zhou L; Lin G; Zhang Y; Yang Z; Zhang H Nanomedicine; 2016 May; 12(4):853-869. PubMed ID: 26772424 [TBL] [Abstract][Full Text] [Related]
14. Conventional and hybrid nanoparticulate systems for the treatment of hepatocellular carcinoma: An updated review. Fawzi Kabil M; Nasr M; El-Sherbiny IM Eur J Pharm Biopharm; 2021 Oct; 167():9-37. PubMed ID: 34271117 [TBL] [Abstract][Full Text] [Related]
15. [Advances in Nanotechnology-Based Drug Delivery Systems in the Treatment of Hepatocellular Carcinoma]. Yang SL; Xiang Y; Yang YJ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Jun; 46(3):384-392. PubMed ID: 38953262 [TBL] [Abstract][Full Text] [Related]
16. Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma. Zhao H; Wu M; Zhu L; Tian Y; Wu M; Li Y; Deng L; Jiang W; Shen W; Wang Z; Mei Z; Li P; Ran H; Zhou Z; Ren J Theranostics; 2018; 8(7):1892-1910. PubMed ID: 29556363 [No Abstract] [Full Text] [Related]
17. Nanophytomedicine Based Novel Therapeutic Strategies in Liver Cancer. Kumar S; Fayaz F; Pottoo FH; Bajaj S; Manchanda S; Bansal H Curr Top Med Chem; 2020; 20(22):1999-2024. PubMed ID: 31724500 [TBL] [Abstract][Full Text] [Related]
18. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin. Zhang X; Li J; Yan M Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448 [TBL] [Abstract][Full Text] [Related]
19. Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma. Hou XY; Jiang G; Yang CS; Tang JQ; Wei ZP; Liu YQ Recent Pat Anticancer Drug Discov; 2016; 11(3):322-31. PubMed ID: 26955964 [TBL] [Abstract][Full Text] [Related]